Transport for anti-cancer nanoparticles
Transport for anti-cancer nanoparticles

Transport for anti-cancer nanoparticles: new method will deliver the drug precisely to the tumor

Transport for anti-cancer nanoparticles

The researchers from the University of Toronto were able to identify a dose level that significantly increases the delivery of cancer drugs directly to the tumor. A determination of that level (or threshold) is able to universally measure the dosage of nanoparticles with that a new generation of cancer therapy can cope with the complex diseases. Ben Ouyan, MD, believes that the dosage of nanoparticles of drugs can be regulated in a simple way, while the effectiveness of the method is very high.

A big advantage is that the dosed transportation of the drug into the tumor deprives the patient of side effects, such as, hair loss, nausea and vomiting. But all previous methods show that only a small number of particles injected into the body reach their destination.


Any new cancer therapies depend on the ability of the medicine to deliver them to the tumor. The new and improved delivery principle is important for nanotechnology, genome editors, immunotherapy.

The liver is the main organ that filters blood, thus providing a great barrier to the advancement of nanoparticles. If the liver has a certain threshold for the rate of absorption, that is, it becomes saturated with nanoparticles, it will no longer be able to cope with higher dosages.

By varying the dose level, the filtering Kupffer cells that line the liver canals are suppressed. In laboratory experiments, mice were injected with a baseline level of 1 trillion nanoparticles. The cells were overwhelmed, and only 12% of the total drug was delivered to the target.


However, the very fact of 12% of drug transport delivery by new methods is already appreciated, since the previous results fluctuated within 0.7%. Thus, the tumor was reduced by 60%. Further research will help to increase the effectiveness in percentage terms.